Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, has been selected as the formulation development partner of Telormedix SA for a pan-European collaborative project. Molecular Profiles will develop both topical and solid dosage formulations for the use in the treatment of psoriasis.
The project, operating under the acronym PAT (Psoriasis Anti-inflammatory Treatment), will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for one of its promising drug candidates, TMX-302, which will use Midatech’s glycan-coated gold nanoparticles, formulated using Molecular Profiles’ expertise.
Dr. Johanna Holldack, chief executive officer at Telormedix, said, “We are absolutely delighted to have secured this funding with such a world-class consortium to bring TMX-302 to preclinical proof of concept. The team at Molecular Profiles will play a key role in developing new oral and topical formulations of TMX-302, both of which are viewed as practicable administration options for the treatment of psoriasis.”
Molecular Profiles’ chief executive officer, Nikin Patel, added, “We are pleased to have been chosen as the formulation development partner for this high-profile, multi-partner project. Our team is ready to apply our technologies to deliver a robust topical and oral formulation. We anticipate that this is just the start of a longer-term clinical development and manufacturing initiative to support a future trial. Beyond the formulation work, our new facility gives Telormedix the reassurance we can also support their finished dosage form production requirements.”